Drugs with targets such as EGFR, ERBB2, MTOR, PARP2, AURKB, MAP2K1 and PLK1 share more similar profiles, which indicates that the inhibition of these targets has specific effects on the in vitro viability and proliferation of cancer cells. This evidence concerns the gene PLK1 and cancer.